Bookbuilding IPO | ₹3,395 Cr | Listed at BSE, NSE | Mon, Jul 14, 2025 - Wed, Jul 16, 2025
Anthem Biosciences IPO is a book build issue of ₹3,395.00 crores. The issue is entirely an offer for sale of 5.96 crore shares of ₹3,395.00 crore.
Anthem Biosciences IPO bidding started from Jul 14, 2025 and ended on Jul 16, 2025. The allotment for Anthem Biosciences IPO was finalized on Jul 17, 2025. The shares got listed on BSE, NSE on Jul 21, 2025.
Anthem Biosciences IPO price band is set at ₹570 per share. The lot size for an application is 26. The minimum amount of investment required by an retail is ₹14,820 (26 shares) (based on upper price). The lot size investment for sNII is 14 lots (364 shares), amounting to ₹2,07,480, and for bNII, it is 68 lots (1,768 shares), amounting to ₹10,07,760.
The issue includes a reservation of up to 1,58,653 shares for employees offered at a discount of ₹50.00 to the issue price.
JM Financial Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Anthem Biosciences IPO RHP for detailed Information.
IPO Open
Mon, Jul 14, 2025
IPO Close
Wed, Jul 16, 2025
Issue Price
₹570 per share
Market Cap (Pre-IPO)
₹31,867.39 Cr
| IPO Date | 14 to 16 Jul, 2025 |
| Listed on | Mon, Jul 21, 2025 |
| Face Value | ₹2 per share |
| Price Band | ₹540 to ₹570 |
| Issue Price | ₹570 per share |
| Lot Size | 26 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹50.00 |
| Total Issue Size | 5,95,75,319 shares (agg. up to ₹3,395 Cr) |
| Offer for Sale | 5,95,75,319 shares of ₹2 (agg. up to ₹3,395 Cr) |
| Share Holding Pre Issue | 56,16,10,051 shares |
| Share Holding Post Issue | 56,16,10,051 shares |
| BSE Script Code / NSE Symbol | 544449 / ANTHEM |
| ISIN | INE0CZ201020 |
Anthem Biosciences IPO offers total 5,95,75,319 shares. Out of which 2,97,08,332 (49.87%) allocated to QIB, 1,18,83,333 (19.95%) allocated to QIB (Ex- Anchor), 89,12,500 (14.96%) allocated to NII 2,07,95,834 (34.91%) allocated to RII and 1,78,24,999 (29.92%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 2,97,08,332 (49.87%) | NA |
| − Anchor Investor Shares Offered | 1,78,24,999 (29.92%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 1,18,83,333 (19.95%) | NA |
| NII (HNI) Shares Offered | 89,12,500 (14.96%) | NA |
| − bNII > ₹10L | 59,41,667 (9.97%) | 16,323 |
| − sNII < ₹10L | 29,70,833 (4.99%) | 8,161 |
| Retail Shares Offered | 2,07,95,834 (34.91%) | 7,99,839 |
| Employee Shares Offered | 1,58,653 (0.27%) | NA |
| Total Shares Offered | 5,95,75,319 (100.00%) |
Investors can bid for a minimum of 26 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,820 |
| Retail (Max) | 13 | 338 | ₹1,92,660 |
| S-HNI (Min) | 14 | 364 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,742 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences IPO raises ₹1,016.02 crore from anchor investors. Anthem Biosciences IPO Anchor bid date is July 11, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Fri, Jul 11, 2025 |
| Shares Offered | 1,78,24,999 |
| Anchor Portion (₹ Cr.) | 1,016.02 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Aug 15, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Oct 14, 2025 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.
The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.
The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.
As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.
As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.
As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.
Competitive Strength
Anthem Biosciences Ltd.'s revenue increased by 30% and profit after tax (PAT) rose by 23% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Total Income | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax | 451.26 | 367.31 | 385.19 |
| EBITDA | 683.78 | 519.96 | 446.05 |
| NET Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves and Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowing | 108.95 | 232.53 | 125.06 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 20.82% |
| ROCE | 26.88% |
| Debt/Equity | 0.05 |
| RoNW | 20.82% |
| PAT Margin | 23.38% |
| EBITDA Margin | 36.81% |
| Price to Book Value | 13.23 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 8.07 | 8.07 |
| P/E (x) | 70.62 | 70.62 |
| Promoter Holding | 76.87% | 74.68% |
| Market Cap | ₹31,867.39 Cr. |
The Anthem Biosciences IPO is subscribed 67.42 times on July 16, 2025 4:59:33 PM (Day 3). The public issue subscribed 5.98 times in the retail category, 192.80 times in the QIB category, and 44.70 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 192.80 | 1,18,83,334 | 2,29,10,95,976 |
| NII | 44.70 | 89,12,500 | 39,84,26,912 |
| bNII (bids above ₹10L) | 51.66 | 59,41,667 | 30,69,18,534 |
| sNII (bids below ₹10L) | 30.80 | 29,70,833 | 9,15,08,378 |
| Retail | 5.98 | 2,07,95,833 | 12,42,99,214 |
| Employee | 6.99 | 1,58,654 | 11,08,692 |
| Total | 67.42 | 4,17,50,321 | 2,81,49,30,794 |
Total Application : 37,94,038
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees and commissions payable to the BRLMs (including any underwriting commission, brokerage and selling commission) | 81.30 |
| 2 | Advertising and marketing expenses | 9.38 |
| 3 | Fees payable to the Registrar to the Offer | 9.42 |
| 4 | Commission/processing fee for SCSBs, Sponsor Bank(s) and Bankers to the Offer. Brokerage and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 8.26 |
| 5 | Printing and distribution of Offer stationery | 1.62 |
| 6 | Regulatory filing fees, book building software fees, listing fees etc. | 4.15 |
| 7 | Fee payable to statutory auditor, namely K.P. Rao & Co., Chartered Accountants | 0.53 |
| 8 | Fees payable to other intermediaries | 2.23 |
| 9 | Fee payable to legal counsels | 9.80 |
| 10 | Miscellaneous | 1.18 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹570.00 | ₹570.00 |
| Open | ₹723.10 | ₹723.05 |
| Low | ₹723.05 | ₹723.05 |
| High | ₹746.70 | ₹747.00 |
| Last Trade | ₹730.35 | ₹730.35 |
Anthem Biosciences IPO is a main-board IPO of 5,95,75,319 equity shares of the face value of ₹2 aggregating up to ₹3,395 Crores. The issue is priced at ₹570 per share. The minimum order quantity is 26.
The IPO opens on Mon, Jul 14, 2025, and closes on Wed, Jul 16, 2025.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Anthem Biosciences IPO using UPI as a payment gateway. Zerodha customers can apply in Anthem Biosciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Anthem Biosciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Anthem Biosciences IPO opens on Mon, Jul 14, 2025 and closes on Wed, Jul 16, 2025.
Anthem Biosciences IPO lot size is 26, and the minimum amount required for application is ₹14,820.
You can apply in Anthem Biosciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Anthem Biosciences IPO will be done on Thursday, July 17, 2025, and the allotted shares will be credited to your demat account by Fri, Jul 18, 2025. Check the Anthem Biosciences IPO allotment status.
The Anthem Biosciences IPO listing date is on Mon, Jul 21, 2025.
